title: Immune response to tissue culture rabies vaccine in subjects who had previous postexposure treatment with Semple or suckling mouse brain vaccine.
abstract: Nerve tissue derived Semple and suckling mouse brain rabies vaccines are still widely used. Patients who experience a new rabies exposure and who were given such vaccines decades earlier are not uncommon in rabies endemic countries. The World Health Organization recommends that persons who have had a previous course of a potent tissue or avian culture rabies vaccine and are reexposed, be given booster infections on days 0 and 3 without rabies immune globulin. Persons who have had previous pre- or postexposure vaccination with a vaccine of unproven potency, should receive a full course of tissue or avian cell vaccine and immune globulin in the event of a new exposure. This study evaluated the immune response in 98 Thai patients who gave a history of rabies postexposure treatment with Semple or suckling mouse brain vaccines 10-50 years previously. The majority (81) had an anamnestic response and developed neutralizing antibodies that were above the recommended minimal acceptable level (0.5 IU ml-1) on day 7. This suggests that they still had immunological memory. A minority of 18% had antibody titers below this level on day 7. However, they all developed titers above 0.5 IU ml-1 on days 14 and 30. Failure to have an accelerated response to revaccination by day 7 did not appear to be related to age or time elapsed since previous nerve tissue derived vaccine administration. It was not possible to predict which subject will or will not have an acceptable level of antibody before day 14. Rabies exposed patients who give a prior history of vaccination with an unknown or nerve tissue derived vaccine should therefore be treated as if they had never been vaccinated.
authors.affiliation: Queen Saovabha Memorial Institute, Thai Red Cross Society, Bangkok.
authors.forename: P
authors.initials: P
authors.lastname: Khawplod
authors.forename: H
authors.initials: H
authors.lastname: Wilde
authors.forename: W
authors.initials: W
authors.lastname: Yenmuang
authors.forename: M
authors.initials: M
authors.lastname: Benjavongkulchai
authors.forename: P
authors.initials: P
authors.lastname: Chomchey
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D001921:Brain; D046508:Culture Techniques; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D051379:Mice; D008875:Middle Aged; D009417:Nerve Tissue; D009500:Neutralization Tests; D011818:Rabies / Q000276:immunology / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000096:biosynthesis* / Q000276:immunology* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D011819:Rabies Vaccines